Literature DB >> 8380285

Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor beta inhibition of lymphokine-activated killer cell generation.

J Koberda1, E A Grimm, R P Moser.   

Abstract

After simultaneous stimulation with anti-CD3 monoclonal antibody (mAb) at 10 ng/ml, anti-CD28 mAb at 125 ng/ml, and interleukin-2 (IL-2) at 20 U/ml, peripheral blood mononuclear cells (PBMC) were partially resistant to immunosuppression by transforming growth factor-beta (TGF beta 2). The doses of TGF beta 2 that inhibit cytotoxicity of IL-2 stimulated cells by 60%-70% were much less effective when the same cells were stimulated with anti-CD3/anti-CD28/IL-2. This favorable stimulation a generated a cell population characterized by high lytic activity, excellent expansion, and a greater resistance to immunosuppressive action of TGF beta 2. The secretion of secondary cytokines important for LAK generation is considered a crucial event, at least partially responsible for the antagonization of TGF beta immunosuppression.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8380285     DOI： 10.1007/bf01229526

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  39 in total

Review 1.  Do CD2 and CD3-TCR T-cell activation pathways function independently?

Authors:  D Kabelitz
Journal:  Immunol Today       Date:  1990-02

2.  T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.

Authors:  P S Linsley; E A Clark; J A Ledbetter
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

Review 3.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

4.  CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.

Authors:  C B Thompson; T Lindsten; J A Ledbetter; S L Kunkel; H A Young; S G Emerson; J M Leiden; C H June
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

5.  CD28 ligation in T-cell activation: evidence for two signal transduction pathways.

Authors:  J A Ledbetter; J B Imboden; G L Schieven; L S Grosmaire; P S Rabinovitch; T Lindsten; C B Thompson; C H June
Journal:  Blood       Date:  1990-04-01       Impact factor: 22.113

6.  A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.

Authors:  G Torre-Amione; R D Beauchamp; H Koeppen; B H Park; H Schreiber; H L Moses; D A Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

7.  Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.

Authors:  S C Yang; L B Owen-Schaub; J A Roth; E A Grimm
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

8.  Two distinct mechanisms of interleukin-2 gene expression in human T lymphocytes.

Authors:  C H June; K M Jackson; J A Ledbetter; J M Leiden; T Lindsten; C B Thompson
Journal:  J Autoimmun       Date:  1989-06       Impact factor: 7.094

9.  Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.

Authors:  P M Anderson; F H Bach; A C Ochoa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

10.  Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.

Authors:  T Espevik; I S Figari; G E Ranges; M A Palladino
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.